Photo by mahdi_bafande from unsplash
Considering the limitation of varying acid suppression of proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect relationship of keverprazan, a novel potassium‐competitive acid blocker,… Click to show full abstract
Considering the limitation of varying acid suppression of proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect relationship of keverprazan, a novel potassium‐competitive acid blocker, in the treatment of duodenal ulcer (DU) compared with lansoprazole.
Keywords:
duodenal ulcer;
efficacy keverprazan;
efficacy;
phase randomized;
keverprazan duodenal;
ulcer phase
Journal Title: Journal of Gastroenterology and Hepatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Gastroenterology and Hepatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!